ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    PUMA-NER-1301
Previous Study | Return to List | Next Study

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01808573
Recruitment Status : Active, not recruiting
First Posted : March 11, 2013
Last Update Posted : May 24, 2018
Sponsor:
Information provided by (Responsible Party):
Puma Biotechnology, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : February 2019
  Estimated Study Completion Date : February 2019